Necitumumab for non-small cell lung cancer

Bibliography

• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
   PubMed Web of Science ®Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii27-39
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Bunn PA, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29:38-44
   PubMed Web of Science ®Google Scholar
• Sacco PC, Maione P, Rossi A, et al. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer. Expert Rev Respir Med 2015;9(3):245-54
   PubMed Web of Science ®Google Scholar
• Normanno N, Bianco C, Strizzi L, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6:243-57
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1S-13S
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9-15
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6
   PubMed Web of Science ®Google Scholar
• Houghton AN, Scheinberg DA. Monoclonal antibody therapies-a « constant » threat to cancer. Nat Med 2000;6:373-4
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11
   PubMed Web of Science ®Google Scholar
• Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25:5777-84
   PubMed Web of Science ®Google Scholar
• Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19:362-9
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-17
   PubMed Web of Science ®Google Scholar
• Lin H, Jiang J, Liang X, et al. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:57-62
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Abouelkhair KM, Al-Masri OA, et al. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung 2011;189:193-8
   PubMed Web of Science ®Google Scholar
• Pujol J-L, Pirker R, Lynch TJ, et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 2014;83:211-18
   PubMed Web of Science ®Google Scholar
• Yang Z-Y, Liu L, Mao C, et al. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev 2014;11:CD009948
   Google Scholar
• O’Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12:795-805
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42
   PubMed Web of Science ®Google Scholar
• Schiller JH, von Pawel J, Schütt P, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1977-85
   PubMed Web of Science ®Google Scholar
• Babu KG, Prabhash K, Vaid AK, et al. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. Onco Targets Ther 2014;7:1051-60
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011;11:1223-31
   PubMed Web of Science ®Google Scholar
• Crawford J, Swanson P, Schwarzenberger P, et al. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2013;8:1510-18
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Tabernero J. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs 2010;11:1434-41
   PubMed Web of Science ®Google Scholar
• De Haard HJ, van Neer N, Reurs A, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999;274:18218-30
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Ludwig D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004;279:2856-65
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang H, Jimenez X, et al. Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy. AACR Meeting Abstracts 2004;64:163-c
   Google Scholar
• Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008;16:216-27
   PubMed Web of Science ®Google Scholar
• Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Zemla A, Wilson IA, et al. Antibody elbow angles are influenced by their light chain class. J Mol Biol 2006;357:1566-74
   PubMed Web of Science ®Google Scholar
• Topper MB, Tonra JR, Pytowski B, et al. Differentiation between the EGFR antibodies necitumumab, cetuximab, and panitumumab: antibody internalization and EGFR degradation. Proc Am Soc Clin Oncol 2011;29:abstract e13022
   Google Scholar
• Patel D, Saxena B, Zhou Q. Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR-expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab. Proc Am Soc Clin Oncol 2011;29:abstract e21075
   Google Scholar
• Prewett M, Tonra JR, Rajiv B, et al. Antitumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human tumor xenograft models. Proc Am Assoc Cancer Res 2004;45:abstract 5353
   Google Scholar
• Prewett M, Tonra JR, Bassi R, et al. Anti-tumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC11F8) in human colon carcinoma xenograft models with enhanced activity in combination with CPT11. Eur J Cancer 2004(Suppl 2):abstract 314
   Google Scholar
• Prewett M, Bassi R, Youssoufian H, et al. The fully Human EGFR antibody IMC-11F8 significantly increases the antitumor effects of cisplatin + gemcitabine in human non-small cell lung cancer models. Proc Am Assoc Cancer Res 2009;69:abstract 2774
   Google Scholar
• Kuenen B, Witteveen PO, Ruijter R, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010;16:1915-23
   PubMed Web of Science ®Google Scholar
• Nokihara H, Yamamoto N, Tamura Y, et al. Phase 1 study of necitumumab (anti-EGFR Monoclonal Antibody) in Japanese patients with advanced solid tumors. Ann Oncol 2014;25:v44-74
   Google Scholar
• A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC). Available from: https://clinicaltrials.gov/ct2/show/study/NCT01763788
   Google Scholar
• Tabernero J, Cervantes A, Delaunoit T, et al. A phase 2 study of IMC-11F8 (necitumumab), a monoclonal antibody (mAb) directed against the epidermal growth factor receptor (EGFR), in combination with mFOLFOX6 chemotherapy in the first line treatment of advanced or metastatic colorectal carcinoma. ESMO 11th World Congress on Gastrointestinal Cancer. 2009;abstract 546
   Google Scholar
• A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer. Available from: https://clinicaltrials.gov/show/NCT01788566
   Google Scholar
• A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/show/NCT01769391
   Google Scholar
• A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02392507
   Google Scholar
• Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015;16:328-37
   PubMed Web of Science ®Google Scholar
• Thatcher N, Hirsch FR, Szczesna A, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol 2014;32:abstr 8008
   Google Scholar
• Petrelli F, Cabiddu M, Borgonovo K, et al. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012;23:1672-9
   PubMed Web of Science ®Google Scholar
• Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013;14:1326-36
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77
   PubMed Web of Science ®Google Scholar
• Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 2015;121:E1-6
   Google Scholar
• Iacono D, Chiari R, Metro G, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer 2015;87:211-19
   PubMed Web of Science ®Google Scholar
• Jiang T, Gao G, Fan G, et al. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung Cancer 2015;87:1-7
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 2014;25:552-63
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 2015;21:976-84
   PubMed Web of Science ®Google Scholar